image
Healthcare - Medical - Devices - NASDAQ - GB
$ 35.4
-1.53 %
$ 1.92 B
Market Cap
30.52
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LIVN stock under the worst case scenario is HIDDEN Compared to the current market price of 35.4 USD, LivaNova PLC is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LIVN stock under the base case scenario is HIDDEN Compared to the current market price of 35.4 USD, LivaNova PLC is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LIVN stock under the best case scenario is HIDDEN Compared to the current market price of 35.4 USD, LivaNova PLC is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LIVN

image
$54.0$54.0$52.0$52.0$50.0$50.0$48.0$48.0$46.0$46.0$44.0$44.0$42.0$42.0$40.0$40.0$38.0$38.0$36.0$36.0$34.0$34.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.25 B REVENUE
8.66%
129 M OPERATING INCOME
288.40%
63.2 M NET INCOME
260.39%
183 M OPERATING CASH FLOW
144.33%
-48.2 M INVESTING CASH FLOW
-19.41%
18.6 M FINANCING CASH FLOW
-13.65%
322 M REVENUE
1.16%
37 M OPERATING INCOME
3.88%
55.9 M NET INCOME
69.61%
78.7 M OPERATING CASH FLOW
54.35%
-10.7 M INVESTING CASH FLOW
42.18%
-3.44 M FINANCING CASH FLOW
-4.94%
Balance Sheet LivaNova PLC
image
Current Assets 429 M
Cash & Short-Term Investments 429 M
Receivables 0
Other Current Assets 0
Non-Current Assets 1.03 B
Long-Term Investments 25.1 M
PP&E 0
Other Non-Current Assets 1 B
29.49 %68.78 %Total Assets$1.5b
Current Liabilities 392 M
Accounts Payable 69.7 M
Short-Term Debt 87 M
Other Current Liabilities 235 M
Non-Current Liabilities 794 M
Long-Term Debt 590 M
Other Non-Current Liabilities 204 M
5.88 %7.34 %19.84 %49.72 %17.22 %Total Liabilities$1.2b
EFFICIENCY
Earnings Waterfall LivaNova PLC
image
Revenue 1.25 B
Cost Of Revenue 383 M
Gross Profit 871 M
Operating Expenses 742 M
Operating Income 129 M
Other Expenses 65.8 M
Net Income 63.2 M
1b1b1b1b1b1b800m800m600m600m400m400m200m200m001b(383m)871m(742m)129m(66m)63mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
69.48% GROSS MARGIN
69.48%
10.30% OPERATING MARGIN
10.30%
5.04% NET MARGIN
5.04%
4.79% ROE
4.79%
2.52% ROA
2.52%
8.05% ROIC
8.05%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis LivaNova PLC
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 63.2 M
Depreciation & Amortization 51.1 M
Capital Expenditures -47.1 M
Stock-Based Compensation 33.9 M
Change in Working Capital 1.31 M
Others 38.1 M
Free Cash Flow 136 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets LivaNova PLC
image
Wall Street analysts predict an average 1-year price target for LIVN of $66.5 , with forecasts ranging from a low of $56 to a high of $72 .
LIVN Lowest Price Target Wall Street Target
56 USD 58.19%
LIVN Average Price Target Wall Street Target
66.5 USD 87.85%
LIVN Highest Price Target Wall Street Target
72 USD 103.39%
Price
Max Price Target
Min Price Target
Average Price Target
757570706565606055555050454540403535May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership LivaNova PLC
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
63.7 K USD 1
6-9 MONTHS
69.9 K USD 1
9-12 MONTHS
3.4 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
LivaNova to Announce First-Quarter 2025 Results LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2025 results on Wed., May 7, 2025, at 1 p.m. London time (8 a.m. Eastern Time). businesswire.com - 3 weeks ago
LivaNova (LIVN) Tops Q4 Earnings Estimates LivaNova (LIVN) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.87 per share a year ago. zacks.com - 1 month ago
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. businesswire.com - 1 month ago
LivaNova to Present at the Barclays Global Healthcare Conference LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should. businesswire.com - 1 month ago
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results LONDON--(BUSINESS WIRE)-- #LIVN--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to rec. businesswire.com - 2 months ago
5 Beaten-Down MedTech Stocks Set to Rebound in 2025 Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape. zacks.com - 3 months ago
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. businesswire.com - 3 months ago
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles. businesswire.com - 4 months ago
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know The mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 4 months ago
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels. zacks.com - 4 months ago
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. businesswire.com - 5 months ago
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock? LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 5 months ago
8. Profile Summary

LivaNova PLC LIVN

image
COUNTRY GB
INDUSTRY Medical - Devices
MARKET CAP $ 1.92 B
Dividend Yield 0.00%
Description LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Contact 20 Eastbourne Terrace, London, W2 6LG https://www.livanova.com
IPO Date Oct. 19, 2015
Employees 2900
Officers Mr. Paul R. Buckman President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement Ms. Natalia Kozmina Chief Human Resources Officer Ms. Lindsey Little Senior Director of Investor Relations Ms. Stephanie Bolton President of Global Epilepsy Deanna Wilke Vice President of Corporate Communications Mr. Philip Kowalczyk Chief Strategy & Corporate Development Officer Mr. Michael D. Hutchinson Senior Vice President, Chief Legal Officer & Company Secretary Mr. Alex Shvartsburg C.M.A. Chief Financial Officer Ahmet Tezel Ph.D. Chief Innovation Officer Mr. Vladimir A. Makatsaria Chief Executive Officer & Director